A Study of Antiaggregatory Effect of Antiplatelet Agents by Platelet Aggregation Test.
- Author:
Won Yong LEE
1
;
Jae Kyu ROH
;
Han Ik CHO
;
Sang Bok LEE
;
Ho Jin MYUNG
Author Information
1. Department of Neurology, College of Medicine, Seoul National University.
- Publication Type:Original Article ; Randomized Controlled Trial
- MeSH:
Adenosine Diphosphate;
Aspirin;
Blood Platelets*;
Cerebral Infarction;
Collagen;
Dipyridamole;
Epinephrine;
Humans;
Infarction;
Platelet Aggregation Inhibitors*;
Platelet Aggregation*;
Ristocetin;
Ticlopidine
- From:Journal of the Korean Neurological Association
1989;7(2):252-257
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
We performed platelet aggregation test in sixty three patients (54 ; cerebral infarction, 9 ; transient ischemic attack) who were randomly treated with aspirin 300mg/day or dipyridamole 150mg/day, singlely or in combination or ticlopidine 500mg/day to evaluate the inhibitory effect of commonly used antiplatelet agents on platelet aggregation. All patients had normal baseline platelet aggregation responses to 4 stimuli ; adenosine diphosphate, epinephrine, collagen and ristocetin. Our study showed no inhibitory response to platelet aggregation at least 7 days after antiplatelet administration in 41.1% (14/34) of aspirin group, 9.5% (2/21) of ticlopidine group, and 100% (8/8) of dipyridamole group. In all of the 9 patients with normal aggregation response to aspirin therapy, platelet aggregation test was converted to inhibitory response by ticlopidine. In contrast, in all of the 2 patients with normal aggregation response to ticlopidine therapy, platelet aggregation test was converted to inhibitory response by aspirin. This study confirms previous findings of platelet inhibition by ticlopidine and aspirin in patients with ischemic cerebrovascular disease. And these results suggest that dipyridamole do not inhibit platelet aggregation in vivo.
